Loading clinical trials...

TERMINATEDPHASE2

A Study of LY3549492 in Healthy Weight Adult Participants

A Parallel-Group, Double-Blind Study to Investigate the Safety and Tolerability of LY3549492 Compared With Placebo in Adult Participants Aged 55 to 80 Years With a BMI of 22 to 25 kg/m2

NCT07085468•Eli Lilly and Company

View on ClinicalTrials.gov

Summary

The main purpose of this study is to evaluate the safety and tolerability of LY3549492 in adult participants with a healthy body max index (BMI) of 22 to 25 kilograms per square meter (kg/m2). Participation in the study will last about 13 months.

Eligibility

Age

55 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Have a body mass index (BMI) within the range of 22 to 25 kilograms per square meter (kg/m2)
•Have had a stable body weight for 3 months prior to screening

Exclusion Criteria

•Have type 1 diabetes, latent autoimmune diabetes in adults, or a history of ketoacidosis or hyperosmolar coma
•Have:
•* type 2 diabetes and on antidiabetic therapy (except type 2 diabetes being managed with diet and/or stable dose of metformin)
•* rare forms of diabetes mellitus, or
•* hemoglobin A1c (HbA1c) \>8%
•Have poorly controlled hypertension
•Have any of the following cardiovascular conditions within 12 months prior to screening:
•* acute myocardial infarction
•* stroke
•* unstable angina, or
+5 more criteria

Locations (21)

Headlands Research - Scottsdale

Scottsdale, Arizona, United States

Valley Clinical Trials, Inc.

Covina, California, United States

Valley Clinical Trials, Inc.

Northridge, California, United States

Peninsula Research Associates

Rolling Hills Estates, California, United States

Artemis Institute for Clinical Research

San Diego, California, United States

JEM Research Institute

Atlantis, Florida, United States

Clinical Research Atlanta

Stockbridge, Georgia, United States

Great Lakes Clinical Trials - Andersonville

Chicago, Illinois, United States

Alliance for Multispecialty Research, LLC

Lexington, Kentucky, United States

Alliance for Multispecialty Research, LLC

Norman, Oklahoma, United States

Key Dates

Start Date

July 21, 2025

Primary Completion Date

August 14, 2025

Completion Date

August 14, 2025

Last Updated

August 29, 2025

Enrollment

ACTUAL participants

Conditions

Healthy

Interventions

LY3549492

DRUG

Placebo

DRUG

Collection of Data and Samples From Healthy Donors for Use in Translational Research

NCT00090662

Healthy Volunteer

View study

RECRUITINGNA

A New Portable Device for Non-invasive Ventilatory Support

NCT06716502

HealthyRespiratory Disease

View study

RECRUITINGPHASE1

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 29, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of LY3549492 in Healthy Weight Adult Participants

Inclusion Criteria

Exclusion Criteria

Collection of Data and Samples From Healthy Donors for Use in Translational Research

A New Portable Device for Non-invasive Ventilatory Support

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

Fecal Microbiota Transplantation for Patients With Autism Spectrum Disorder.

Turkish Validity and Reliability Study of PRevention of Toxic Chemicals in the Environment for Children Tool

A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity